1. Home
  2. ANGI vs IFRX Comparison

ANGI vs IFRX Comparison

Compare ANGI & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Angi Inc.

ANGI

Angi Inc.

HOLD

Current Price

$6.10

Market Cap

233.4M

ML Signal

HOLD

Logo InflaRx N.V.

IFRX

InflaRx N.V.

HOLD

Current Price

$2.24

Market Cap

266.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ANGI
IFRX
Founded
1995
2007
Country
United States
Germany
Employees
N/A
N/A
Industry
Advertising
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
233.4M
266.6M
IPO Year
2017
2017

Fundamental Metrics

Financial Performance
Metric
ANGI
IFRX
Price
$6.10
$2.24
Analyst Decision
Buy
Strong Buy
Analyst Count
7
4
Target Price
$17.00
$6.25
AVG Volume (30 Days)
1.0M
1.4M
Earning Date
05-05-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
1242.86
N/A
EPS
N/A
N/A
Revenue
$736,386,000.00
N/A
Revenue This Year
$3.25
N/A
Revenue Next Year
$3.76
N/A
P/E Ratio
N/A
N/A
Revenue Growth
47.60
N/A
52 Week Low
$4.53
$0.74
52 Week High
$19.42
$2.95

Technical Indicators

Market Signals
Indicator
ANGI
IFRX
Relative Strength Index (RSI) 56.90 58.51
Support Level $4.67 $0.87
Resistance Level $6.62 $2.94
Average True Range (ATR) 0.41 0.21
MACD 0.12 0.06
Stochastic Oscillator 93.29 63.64

Price Performance

Historical Comparison
ANGI
IFRX

About ANGI Angi Inc.

Angi Inc connects quality home service professionals with consumers across different categories, from repairing and remodeling to cleaning and landscaping. It operates through brands like Angi, HomeAdvisor, and Handy. The company has three operating segments, namely, Ads and Leads, Services, and International (Europe and Canada). A majority of its revenue is generated from the Ads and Leads segment, which provides professionals the capability to engage with potential customers, including quoting and invoicing services, and provides consumers with tools and resources to help them find professionals nationwide for home repair, maintenance, and improvement projects. Geographically, the company derives its key revenue from the United States and also has a presence in other countries.

About IFRX InflaRx N.V.

InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

Share on Social Networks: